<sup>177</sup> Lu‐PSMA radioligand therapy effectiveness in metastatic castration‐resistant prostate cancer: An updated systematic review and meta‐analysis-Reference-Cited by-同舟云学术

¹⁷⁷ Lu‐PSMA radioligand therapy effectiveness in metastatic castration‐resistant prostate cancer: An updated systematic review and meta‐analysis

Published:2022-03-14 Issue:7 Volume:82 Page:826-835
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:The Prostate

Author:

Sadaghiani Mohammad S.¹,Sheikhbahaei Sara¹^ORCID,Werner Rudolf A.²,Pienta Kenneth J.³,Pomper Martin G.¹³,Gorin Michael A.⁴⁵,Solnes Lilja B.¹,Rowe Steven P.¹³^ORCID

Affiliation:

1. The Russell H. Morgan Department of Radiology and Radiological Science Johns Hopkins University School of Medicine Baltimore Maryland USA

2. Department of Nuclear Medicine University Hospital Würzburg Würzburg Germany

3. Department of Urology, The James Buchanan Brady Urological Institute Johns Hopkins University School of Medicine Baltimore Maryland USA

4. Urology Associates and UPMC Western Maryland Cumberland Maryland USA

5. Department of Urology University of Pittsburgh School of Medicine Pittsburgh Pennsylvania USA

Publisher

Wiley

Subject

Urology,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pros.24325

Reference84 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology

3. Expression of Prostate-Specific Membrane Antigen in Normal and Malignant Human Tissues

4. Lutetium177PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy

5. A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177–labeled Prostate-specific Membrane Antigen–targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic value of pretherapeutic 68Ga-PSMA-11-PET based imaging parameters in mCRPC patients treated with PSMA radioligands;Nuklearmedizin - NuclearMedicine;2024-08-29

2. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II—2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer;European Urology;2024-08

3. Analysis of Molecular Imaging and Laboratory Baseline Biomarkers in PSMA-RLT: Whole-Body Total Lesion PSMA (TLP) Predicts Overall Survival;Cancers;2024-07-26

4. Imaging and therapy in prostate cancer using prostate specific membrane antigen radioligands;British Journal of Radiology;2024-05-11

5. PSMA-Targeted Radiopharmaceuticals for Prostate Cancer Diagnosis and Therapy;The Cancer Journal;2024-05